SynapDx is a Massachusetts-based startup building a blood-based risk-assessment test for autism that combines genome sequencing, RNA measurements, and proprietary informatics. Its core product measures RNA copied from many genes and correlates those signals with clinical autism diagnoses to help flag children for earlier clinical evaluation. The company uses standard genome sequencers (e.g., Illumina) and layers on proprietary analytics as its differentiator. SynapDx recently closed a $15.4M financing led by Google Ventures to advance development and validation. It launched a 660-child, 20-site clinical study earlier this year and does not yet have a commercial launch timeline. While focused on autism today, the company says the approach could be applied to other neurodevelopmental disorders in the future. SynapDx is developing a blood-based autism spectrum disorder (ASD) diagnostic test intended to help clinicians identify children with autism earlier. The company is conducting clinical development and collaborates with ASD experts at leading institutions across the U.S. It plans to use new funding to support further studies of its early ASD diagnostic test. SynapDx has a strategic partnership with Illumina and counts investors including North Bridge Venture Partners, General Catalyst Partners and LabCorp. The company announced a $6 million financing in December 2012 and a $2 million investment from LabCorp prior to the current round. SynapDx was founded in 2010 and is based in Lexington, Mass. SynapDx develops a blood-based diagnostic test to detect autism spectrum disorder (ASD) earlier in children and plans to build a broader pediatric neurodevelopment testing offering. The company provides laboratory diagnostic services to physicians and collaborates with ASD experts at leading institutions, including Boston Children’s Hospital. SynapDx said it will use new funding to support clinical development and to fund further studies slated to begin later this year. Its disclosed investors include North Bridge Venture Partners and General Catalyst Partners. SynapDx was founded in 2010 and is based in Lexington, Massachusetts. The company recently announced a $6 million financing and secured a $2 million investment from Laboratory Corporation of America (LabCorp) to advance its diagnostic program. SynapDx is developing a blood-based diagnostic test that measures RNA gene expression to distinguish children at higher risk for autism spectrum disorders. The test is designed to identify children with ASD by age 36 months and to hasten the diagnostic process so at-risk children can access evaluations and treatment earlier. SynapDx obtained an exclusive license to discoveries from Boston Children’s Hospital and collaborates with ASD and gene expression experts at leading institutions. The company will use financing proceeds to fund further studies slated to begin in 2013 and to expand its executive team. SynapDx raised $6 million from North Bridge Venture Partners and General Catalyst Partners to support development. The company was founded in 2010, is based in Southborough, Mass., and is led by CEO Stanley Lapidus. SynapDx develops and aims to commercialize diagnostic blood-based tests for the early detection of autism. The company is focused on creating an objective blood-based diagnostic test to enable earlier diagnosis, more rapid intervention, and improved outcomes. SynapDx is based in Waltham, Mass. and completed a $9M Series A financing. The company’s founder, president and CEO is Stanley N. Lapidus, who holds 31 issued patents and previously founded and led Cytyc, EXACT Sciences, and Helicos BioSciences. Co-founders include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.

Total raised

$32M

Funding rounds

5

Latest round

Equity

Latest activity

Jul 2013